Literature DB >> 29935691

Palliative Management of Advanced Peritoneal Carcinomatosis.

Laura A Lambert1, Ryan J Hendrix2.   

Abstract

Despite advances in the management of peritoneal carcinomatosis, morbidity remains high with survival often measured in weeks to months. Patients are often subjected to symptoms and complications that impact quality of life. Much of the management revolves around palliation of symptoms and providing support and resources to address emotional and existential concerns. This article reviews surgical and nonsurgical palliative treatments for the symptoms and complications associated with advanced, incurable peritoneal carcinomatosis. It is important that providers caring for patients with peritoneal carcinomatosis be knowledgeable in the palliative management of this condition, including the usefulness of early palliative care referral.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascites; Carcinomatosis; Hospice; Obstruction; Palliative

Mesh:

Year:  2018        PMID: 29935691     DOI: 10.1016/j.soc.2018.02.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  6 in total

1.  Incomplete Cytoreduction of Colorectal Cancer Peritoneal Metastases: Survival Outcomes by a Cytoreduction Score.

Authors:  Paul H Sugarbaker; David Chang
Journal:  Visc Med       Date:  2022-02-23

Review 2.  Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery.

Authors:  Biying Huang; Ioannis Rouvelas; Magnus Nilsson
Journal:  Ann Gastroenterol Surg       Date:  2022-03-24

3.  The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations.

Authors: 
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

4.  Type I IFN, Ly6C+ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination.

Authors:  Allison M Dyevoich; Karen M Haas
Journal:  Mol Cancer Ther       Date:  2020-03-18       Impact factor: 6.261

5.  A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models.

Authors:  Iaroslav Sautkin; Wiebke Solass; Frank-Jürgen Weinreich; Alfred Königsrainer; Martin Schenk; Karolin Thiel; Marc A Reymond
Journal:  Pleura Peritoneum       Date:  2019-08-15

6.  Current management of malignant bowel obstructions: a survey of acute care surgeons and surgical oncologists.

Authors:  Josh Bleicher; Laura A Lambert; Courtney L Scaife; Alexander Colonna
Journal:  Trauma Surg Acute Care Open       Date:  2021-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.